Each year, Aging Research & Drug Discovery Meeting hosts top-class thought leaders and participants from organizations and universities around the world. The last week of August in Copenhagen is the time and place to be to discuss the problems of our aging population and new advancements in longevity. We are happy to see our portfolio companies Ani Biome, Turn Biotechnologies, Rubedo Life Sciences, and Haut.AI among the sponsors and speakers of the event. We are also happy to share that our general partner, Garri Zmudze, will be judging this year’s startup pitch together with Katerina Stroponiati from Brilliant Minds, Jens Nielsen from BioInnovation Institute and with Jitka Kolářová, Lead for Innovations in Health and Healthcare at World Economic Forum, as a moderator. For more information, visit the ARDD website here: https://lnkd.in/dmRE-qJv See you in Copenhagen!
LongeVC
Wagniskapital- und Private-Equity-Auftraggeber
Paradiso, Lugano 3.217 Follower:innen
We invest in an ageless future.
Info
We support early-stage biotech and longevity-focused founders that are changing the world. We help these companies gain industrial momentum, raise capital, and shape the future of biotech. Our approach is based on growing the whole ecosystem. We fund companies in complementary industrial sectors, empowering us to build a broad community of biotech innovators that can exchange their expertise and build on each other's successes.
- Website
-
http://www.longevc.com
Externer Link zu LongeVC
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Paradiso, Lugano
- Art
- Privatunternehmen
- Gegründet
- 2020
Orte
-
Primär
Via Calprino 18
Paradiso, Lugano CH-6909, CH
Beschäftigte von LongeVC
Updates
-
Opportunities in the market connected with pet and animal health are huge. The segments of pet longevity, veterinary services, therapeutics, consumables, pet tech, animal health, digital services and e-commerce combined are worth $542 billion. For this reason, we applaud AniVC, a freshly launched early-stage venture fund for the pet industry, which has been done through the great efforts of many people in the LongeVC ecosystem, including our founding partner Garri Zmudze. An ageless future doesn’t (and shouldn’t!) need to be limited to only humans - congratulations to the team on their launch today. https://lnkd.in/de8bzVe6
Ani.VC Launches a Fund for Pets and First Investment in DOG PPL
businesswire.com
-
With numerous biotech startups in the market, it's crucial for investors to identify those with potential for their portfolios. Equally important, startup founders need to know what information to present to investors to stand out and demonstrate their expertise and value. In a recent piece for Clinical Leader, LongeVC’s Artem A. Trotsyuk, Sergey Jakimov, Artemy Shumskiy, and Vlad Cernouţan share that VCs and investors looking to fund biotech and medtech companies are interested in more than just the specifics of the clinical trial itself. They want to see a strong team with clinical trial experience and a plan for what to do if things don't go according to plan. To learn more, read the full article here: https://lnkd.in/d-6TFJGC #Biotech #BiotechInvesting #VC #MedTech #VentureCapital
What Clinical Trial Information Do VCs And Investors Actually Want?
clinicalleader.com
-
Existing technologies are still limited in their ability to target many potential drug targets that could greatly benefit human health. 70% of these drug targets are too complex for small molecules and cannot be reached by biologics, and some can only be addressed through injectable therapeutics. LongeVC's portfolio company Unnatural Products Inc. is exploring beyond the traditional 'rule of five' for drug discovery. They are focusing on macrocyclic peptides, which, despite not conforming to the usual rules due to their size and structure, have shown promise for excellent gut absorption, cellular uptake, and targeting challenging proteins involved in diseases like cancer. To read more about UNP, check the editor’s pick in Nature Biotechnology by Michael Eisenstein here: https://lnkd.in/dzZcnUmx Nature Biotechnology annually spotlights companies receiving significant early-stage funding. Congratulations to the Unnatural Products team on the feature!
Editor’s pick: Unnatural Products - Nature Biotechnology
nature.com
-
Big money is pouring into biotech and healthcare startups in 2024. According to Crunchbase, 115 funding rounds attracted record investments, surpassing the $100 million mark so far this year. This surge is fueled by a perfect storm of factors: advancements in AI that dramatically speed up drug discovery, an aging population with rising chronic diseases demanding new treatments, and supportive regulations. LongeVC’s Sergey Jakimov shared his views on this topic with Jules ADAM in his recent article for Labiotech.eu. In his commentary, Sergey mentioned that biotech stocks are gaining momentum due to successful FDA approvals for earlier-stage companies. This success is validating the sector and making investors more willing to back promising private companies. Pharmaceutical company acquisitions also play a role in validating biotech investment. Read the full, in-depth piece here: https://lnkd.in/dSUv6kWS Thank you for mentioning our opinion and for this nice read, Jules ADAM! #Biotech #BiotechInvesting #VC #AI #DrugDiscovery #FDA
Biotech megadeals: Exploring the surge in $100M deals
https://www.labiotech.eu
-
We had an incredible time yesterday at the #LongevityFoundersForum on the stage with like-minded longevity investors. Kudos to our field colleagues for sharing their opinions on various longevity topics - Oliver Colville, Michael Greve, and Nils Regge. Also our heartfelt thanks to the event organizers Longevity.Technology & Phil Newman for inviting us. Your commitment to organizing insightful events has nurtured a strong sense of open community. In other words, London never disappoints. To learn more: https://lnkd.in/d6x4fzrs
-
-
The longevity market focused on extending the human lifespan and improving health in later years, is rapidly expanding. The sector attracts significant investments from VCs, the pharmaceutical industry and tech giants, aiming to revolutionize the way we approach aging and age-related diseases. It is great to see more longevity-focused events appearing on the conference scene - meeting to discuss, share knowledge and network is crucial for all of us. In a few weeks, during London Tech Week on June 10-11, LongeVC managing partner Sergey Jakimov will attend one of the panels during the Founders Longevity Forum. The event, co-organized in partnership with Longevity.Technology, will gather some of the industry’s greatest leaders, including Insilico Medicine CEO and Head of LongeVC Advisory Board Alex Zhavoronkov, Bruno Balen, founder of Ani Biome, one of LongeVC portfolio companies, Todd White (VitaDAO), Aubrey de Grey (Longevity Escape Velocity (LEV) Foundation), Petr Sramek (LongevityTech.fund), Bhuvan Srinivasan (Ultrahuman), Christin Glorioso, MD PHD (NeuroAge Therapeutics), Joanna Bensz (Longevity Center Europe) and more. If you’d like to connect with Sergey Jakimov or Garri Zmudze during the event, drop them a message or contact us via [email protected]. https://lnkd.in/d3cDSEe6 #Longevity #BiotechInvesting #FoundersForum #London Founders Forum Group Carolyn Dawson
LongeVC’s Sergey Jakimov Speaking at Founders Longevity Forum During London Tech Week on 10-11 June
longevc.com
-
According to the World Health Organization, the number of people aged 60 and above is expected to double from 1 billion in 2020 to 2.1 billion by 2050. While many companies working in the longevity field are looking at how to assist people in living healthier and longer lives, there is still a lot of work to be done in terms of translating scientific advances into practical clinical interventions. Recently, LongeVC’s Sergey Jakimov and Artem A. Trotsyuk sat down with Drug Discovery’s Brian K. Buntz to discuss these topics. Sergey and Artem shared some insights into our portfolio companies and explained the focus of our fund, what we look for when investing in new startups, and how to distinguish legitimate applications from "snake oil" in the industry. You can read the full piece here: https://lnkd.in/dVC9C-vh. Thank you for this in-depth conversation and a great, research-based article, Brian! #DrugDiscovery #Biotech #BiotechInvesting #AI WTWH Media LLC
LongeVC's Jakimov and Trotsyuk on the future of longevity biotech
https://www.drugdiscoverytrends.com
-
A great chance to share the stage alongside fellow like-minded longevity experts. Thanks to #Rejuvenationstartupsummit and Berlin for the opportunity and hospitality. And kudos to the longevity colleagues Patrick Burgermeister, Marc P. Bernegger, Jens Eckstein, Alex Colville, Jan Adams for the chance to engage.
-
-
Imagine being able to enhance any drug treatment by adding functional proteins or targeting specific cells without changing their genetic makeup. This opens up a world of possibilities for personalized and precise medicine. CatenaBio (courtesy of its CysTyr™ platform and Catenase™ enzyme) has developed a technology that can modify and combine proteins freely, enabling the creation of novel therapeutics in oncology, autoimmune disorders, and vaccine development. This technology removes limitations on the size, number, and type of molecules that can be attached to a single protein - game-changing for future medical therapies. Welcome, CatenaBio, to the LongeVC portfolio - we look forward to supporting you in the next stage of growth. https://lnkd.in/dm9TZyBX Marco Lobba, Ph.D., Jennifer Doudna, Matthew Francis, Saurabh Johri, Rick Kendall #Biotech #VC #Longevity #Medtech
LongeVC Joins CatenaBio’s $2.35M Seed Extension Round
longevc.com